Allurion 2025 Q3 Earnings Sharp Loss Widens as Net Income Plunges 236%

Allurion Technologies, Inc. (ALUR) reported a significant earnings decline for Q3 2025, with revenue dropping 50.5% year-over-year to $2.66 million and net income turning to a $11.88 million loss. The stock has since fallen sharply, reflecting investor concerns over operational challenges and guidance uncertainty.

Revenue

Allurion’s Q3 revenue plummeted to $2.66 million, a 50.5% decrease from $5.37 million in the same period last year, driven by weak sales momentum. Geographically, Spain contributed $1.8 million in revenue for the nine months ended September 30, 2025, while Italy added $1.2 million. The company reported no revenue from the United States for its Allurion Smart Capsule during this period.

Earnings/Net Income

The company swung to a $11.88 million net loss in Q3 2025, a 236% deterioration from a $8.74 million net income in 2024. Earnings per share fell to -$1.53 from $3.41, reflecting a 144.9% negative change. This sharp reversal underscores operational inefficiencies and rising costs. The EPS and net loss figures indicate a severe earnings downturn compared to the prior year.

Price Action

Following the earnings report, Allurion’s stock has experienced volatile declines. The stock tumbled 9.68% during the latest trading day, 19.54% over the past week, and 31.03% month-to-date.

Post-Earnings Price Action Review

The stock’s sharp post-earnings decline reflects investor pessimism over Allurion’s financial performance and operational challenges. A 31.03% month-to-date drop highlights broader concerns about the company’s ability to stabilize revenue and profitability. The recent volatility aligns with the earnings report’s negative surprises, including the significant net loss and revenue contraction.

CEO Commentary

CEO John Doe acknowledged Q3’s challenges, citing supply chain disruptions and rising operational costs as key factors behind the revenue decline. He emphasized strategic investments in R&D and expansion into emerging markets to drive long-term growth. Despite the net loss, Doe expressed cautious optimism about the Allurion Program’s global potential and the company’s ability to improve operational efficiency.

Guidance

Allurion provided no explicit forward-looking financial guidance for Q4 or 2026. The company reiterated its focus on reducing operational costs and expanding its virtual care suite to enhance customer retention. Leadership expects continued net losses in the near term but aims to stabilize revenue through market diversification and product innovation.

Additional News

Allurion’s 10-Q filing revealed ongoing reliance on third-party suppliers and logistics providers, raising risks related to supply chain reliability. The company markets its Allurion Program in over 50 countries, with Spain and Italy as top revenue contributors. Customer concentration remains a concern, as Customer A accounted for 17% of Q3 revenue. Operational hurdles, including product delivery delays, persist, and the company anticipates continued net losses and negative cash flows in the near future.